News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
France’s NicOx SA to Buy Back Eye Drug Rights from Pfizer Inc. (JOBS)
August 6, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- French biotech firm NicOx (NCOX.PA) will buy back the rights to develop and market a drug that seeks to treat eye disease glaucoma from U.S. drugmaker Pfizer (PFE.N) and said it was open to finding another partner.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Pfizer
MORE ON THIS TOPIC
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
September 9, 2026
·
2 min read
·
Nick Paul Taylor
IPO
2026 IPO stock tracker: How newly public biotechs are performing
September 9, 2026
·
1 min read
·
Gabrielle Masson
IPO
Steady stream of crossover rounds stock biotech’s IPO pipeline
September 9, 2026
·
7 min read
·
Annalee Armstrong
Insights
Can Benelux turn scientific strength into larger biotech scale?
September 8, 2026
·
4 min read
·
Jennifer C. Smith-Parker